Increasing risk of diabetes mellitus according to liver function alterations in electronic workers

Kyoungho Lee1, Joohee Han1, Soo-Geun Kim2*

1Samsung Health Research Institute, Samsung Electronics, Yongin-City, and 2Department of Occupational Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Keywords
Diabetes mellitus, Liver function, Workers

*Correspondence
Soo-Geun Kim
Tel.: +82-2-2001-2445
Fax: +82-2-2001-2626
E-mail address: soogeun.kim@samsung.com

J Diabetes Invest 2014; 5: 671–676
doi: 10.1111/jdi.12202

INTRODUCTION
According to a 2005 report from the World Health Organization, 170 million people are estimated to suffer from diabetes around the world1. This number is expected to rise to approximately 300 million by 20251,2. The prevalence of diabetes was less than 1% in Korea in the 1970s. However, a total of 2,694,220 diabetes patients (7.75% of the people) were confirmed between the ages of 20 and 79 years in 2003. Nearly 10% of all patients with diabetes were new patients3.

Increased activity of liver enzymes, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltranspeptidase (GGT), are indicators of hepatocellular injury, which are also associated with insulin resistance4, metabolic syndrome5,6 and type 2 diabetes7,8. In particular, serum GGT concentrations showed a strong dose–response relationship with incident diabetes in a study of healthy Korean men9. Serum GGT level was shown to be related to chronic diseases, such as hypertension, hyperlipidemia, obesity and diabetes, and metabolic syndrome, in Korea10,11. In a previous study, the results of Coronary Artery Risk Development in Young Adult (CARDIA) as a prospective cohort study among 20,000 participants in 2003 showed a strong association between GGT and fasting plasma glucose (FPG)12,13.

However, although an increasing number of studies have been using indicators of liver function tests, correlation studies regarding FPG as a diabetes diagnostic indicator and liver
function deterioration are still insufficient. The objective of the present study was to determine the association between altered levels of FPG and levels of liver enzymes, such as AST, ALT and GGT, after adjustment for potential risk factors including age, sex and so on from health examinations among semiconductor workers.

MATERIALS AND METHODS

Selection of Participants

Initially, 19,534 semiconductor workers (mean age 32 years, range 20–59 years) were recruited from a health examination center between January 2002 and December 2010. We then selected 9,907 semiconductor workers who underwent three cycles of clinical health examination (follow-up rate 50.7%). A total of 514 participants were excluded from the study if any of the following were detected from their self-questionnaire and clinical data: a history of hepatitis, the presence of abnormal liver function, diabetes, hepatitis B or hepatitis C virus-positive cases and FPG ≥126 mg/dL. A total of 9,393 people were selected as final participants. Follow-up duration between the first and last health examinations was 73 months (range 18–105 months).

Group 1 and 4 were stationary groups of those with normal liver enzyme levels in the first and last health examinations (G1), and abnormal liver enzyme levels in the first and last health check-up (G4), respectively. Groups 2 and 3 were altered groups of those with abnormal liver enzyme levels in the first health examination, which became normal in the last (G2), and from normal liver enzymes level to abnormal (G3), respectively. All participants gave written, informed consent, and the protocol was approved by the institutional review board committee of the Kangbook Samsung Hospital.

Analysis of Clinical Biomarkers

General factors that influenced the results of the examinations were used to analyze age, sex and body mass index (BMI), and the factors of liver function were used to analyze AST, ALT and GGT by an automatic analyzer. A diagnosis of diabetes was made for FPG ≥126 mg/dL by the Hexokinase method. Height, weight, waist circumference, systolic and diastolic blood pressure were measured, and BMI (kg/m²) was calculated using body height and weight.

Total cholesterol (TC) and triglyceride (TG) were measured by the enzymatic calorimetric test, low-density lipoprotein cholesterol was measured with the homogeneous enzymatic colorimetric test, and high-density lipoprotein-cholesterol was measured with the selective inhibition method (Advia 1650, Bayer, Germany). Hepatitis B surface antigen (Isomedic, ICN, Costa, MA, USA) and hepatitis C antibody (Wizard 1470, Wallac, Finland) were measured using a radioimmunometric assay. Abdominal ultrasounds were carried out with a 3.5-MHz transducer (Logic Q700 MR; GE, Milwaukee, WI, USA) by 12 experienced radiologists who were unaware of the aims of the study and blinded to laboratory values. Images were captured in a

| Categories          | n (%) | FPG levels in last health check-up |
|---------------------|-------|----------------------------------|
|                     |       | GM     | GSD    | P-value | Duncan |
| Sex                 |       |        |        |         |        |
| Male                | 8,355 | (88.9) | 95.98  | 1.11    |        |
| Female              | 1,039 | (11.1) | 92.07  | 1.10    |        |
| Total               | 9,394 | (100)  | 95.54  | 1.11    | <0.01  |
| Age (years)         |       |        |        |         |        |
| 26–39               | 5,985 | (63.7) | 95.10  | 1.10    | A      |
| 40–49               | 3,292 | (35.0) | 96.24  | 1.12    | A/B    |
| 50–59               | 117   | (1.2)  | 98.53  | 1.12    | A/B    |
| Total               | 9,394 | (100)  | 95.54  | 1.11    | <0.01  |
| Drinking frequency  |       |        |        |         |        |
| Non-drinkers        | 1,665 | (18.0) | 93.80  | 1.10    | A      |
| Two to three times/month | 4,696 | (50.9) | 95.26  | 1.11    | A      |
| One to two times/week | 2,473 | (26.8) | 96.75  | 1.12    | A/B    |
| Three to four times/week | 359  | (3.9)  | 97.87  | 1.11    | B/C    |
| Every day           | 38    | (0.4)  | 98.80  | 1.09    | C      |
| Total               | 9,231 | (100)  | 95.59  | 1.11    | <0.01  |
| Smoking status      |       |        |        |         |        |
| Non-smokers         | 3,228 | (37.4) | 94.30  | 1.11    | A      |
| Ex-smokers          | 2,238 | (25.9) | 96.07  | 1.11    | A      |
| Smokers             | 3,176 | (36.8) | 96.21  | 1.11    | B      |
| Total               | 8,642 | (100)  | 95.59  | 1.11    | <0.01  |
| Duration of smoking |       |        |        |         |        |
| Less than 5 years   | 857   | (16.4) | 95.18  | 1.11    | A      |
| 5–10 years          | 1,238 | (23.7) | 95.85  | 1.11    | A/B    |
| 10–20 years         | 2,707 | (51.9) | 96.09  | 1.11    | A/B    |
| 20–30 years         | 412   | (7.9)  | 97.28  | 1.11    | A/B    |
| >30 years           | 5     | (0.1)  | 101.62 | 1.13    | B      |
| Total               | 5,219 | (100)  | 95.59  | 1.11    | <0.01  |
| Diet pattern        |       |        |        |         |        |
| Vegetarian          | 325   | (3.5)  | 93.23  | 1.10    | A      |
| Balanced diet       | 7,282 | (78.3) | 95.44  | 1.11    | A      |
| Meat eater          | 1,692 | (18.2) | 96.37  | 1.12    | B      |
| Total               | 9,299 | (100)  | 95.59  | 1.11    | <0.01  |
| Liver status        |       |        |        |         |        |
| Fatty liver         | 2,656 | (28.6) | 98.32  | 1.13    |        |
| Non-fatty liver     | 6,634 | (71.4) | 94.36  | 1.10    |        |
| Total               | 9,290 | (100)  | 95.49  | 1.11    | <0.01  |
| Sweated exercise    |       |        |        |         |        |
| Non-exercise        | 3,625 | (42.1) | 95.01  | 1.11    | A      |
| One to two times/week | 3,339 | (38.8) | 95.64  | 1.11    | A/B    |
| Three to four times/week | 1,416 | (16.5) | 96.25  | 1.11    | A/B/C  |
| Five to six times/week | 139   | (1.6)  | 94.13  | 1.10    | B/C    |
standard manner with the patient in the supine position with the right arm raised above the head\(^{14}\). An ultrasonographic diagnosis of fatty liver was defined as the presence of a diffuse increase of fine echoes in the liver parenchyma compared with the kidney or spleen parenchyma\(^{15}\). Ultrasonographic diagnosis of fatty liver was determined by the radiologists using live images.

### Statistical Analysis

All results were calculated using the mean value and standard deviation for each of the parameters considered, and were checked for statistical significance using analysis of variance (ANOVA) and Student’s t-test for FPG levels and liver function status (normal vs abnormal) by sex. The differences were confirmed using the Duncan’s post-hoc test by ANOVA.

Estimates of elevation to FPG at the last health screening, covariates including sex, age, BMI, diet pattern, drinking frequency, smoking status, physical activity and systolic blood pressure were determined by deriving the parameter estimate (\(\beta\)) and its \(P\)-value using multiple linear regressions. For all tests, a two-sided \(P < 0.05\) was considered statistically significant. Data analyses were carried out using the SAS 9.2 statistical software package (SAS Inc., Cary, NC, USA).

### Table 2 | Geometric means and geometric standard deviation of biomarkers in blood from physical examinations

| Variables | First check-up | Second check-up | Third check-up |
|-----------|---------------|----------------|---------------|
| n | GM | GSD | n | GM | GSD | n | GM | GSD |
| FPG | 9,394 | 91.68 | 1.09 | 9,394 | 94.16 | 1.09 | 9,394 | 95.54 | 1.11 |
| AST\(^*\) | 9,393 | 23.68 | 1.35 | 9,394 | 22.84 | 1.36 | 9,394 | 22.92 | 1.39 |
| ALT\(^†\) | 9,394 | 25.58 | 1.71 | 9,394 | 24.61 | 1.71 | 9,394 | 24.09 | 1.73 |
| GGT\(^†\) | 9,393 | 23.95 | 1.93 | 9,394 | 26.72 | 1.96 | 9,394 | 28.51 | 2.04 |
| TC | 9,394 | 193.01 | 1.19 | 9,394 | 188.87 | 1.19 | 9,394 | 197.52 | 1.19 |
| TG | 9,394 | 119.54 | 1.67 | 9,394 | 121.10 | 1.68 | 9,394 | 119.79 | 1.70 |
| HDL-C | 9,394 | 51.81 | 1.23 | 9,394 | 51.46 | 1.22 | 9,394 | 51.66 | 1.25 |
| LDL-C | 9,394 | 112.13 | 1.30 | 9,394 | 110.20 | 1.30 | 9,394 | 117.51 | 1.30 |
| BMI | 9,391 | 23.59 | 1.13 | 9,391 | 23.82 | 1.13 | 9,394 | 24.02 | 1.13 |
| SBP | 9,392 | 114.79 | 1.11 | 9,394 | 114.43 | 1.11 | 9,393 | 116.02 | 1.11 |
| DBP | 9,392 | 73.98 | 1.14 | 9,394 | 74.23 | 1.13 | 9,393 | 74.10 | 1.12 |

*Alanine aminotransferase (ALT): normal is <40 IU/L for men and <35 IU/L for women, and abnormal is \(\geq 40\) IU/L for men and \(\geq 35\) IU/L for women. †Aspartate aminotransferase (AST): normal is <40 IU/L for men and <35 IU/L for women, and abnormal is \(\geq 40\) IU/L for men and \(\geq 35\) IU/L for women. ‡Gamma-glutamyltranspeptidase (GGT): normal is <63 IU/L for men and <35 IU/L for women, and abnormal is \(\geq 63\) IU/L for men and \(\geq 35\) IU/L for women. BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.

### Table 3 | Multiple linear regression for fasting plasma glucose levels by liver function biomarkers, aspartate aminotransferase, alanine aminotransferase and gamma-glutamyltranspeptidase

| Variable | Parameter estimate (\(\beta\)) | Standard error | \(P\)-value |
|----------|-----------------------------|----------------|-------------|
| Intercept | 3.497 | 0.062 | <0.01 |
| AST | 0.013 | 0.006 | 0.03 |
| ALT | 0.010 | 0.004 | <0.01 |
| GGT | 0.016 | 0.002 | <0.01 |
| Sex | 0.009 | 0.004 | 0.04 |
| Age | 0.001 | 0.000 | <0.01 |
| BMI | 0.096 | 0.011 | <0.01 |
| Diet pattern | 0.000 | 0.003 | 0.97 |
| Drinking frequency | 0.006 | 0.002 | <0.01 |
| Smoking status | 0.002 | 0.001 | 0.16 |
| Systolic BP | 0.135 | 0.011 | <0.01 |

\(n = 8,379\). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; GGT, gamma-glutamyltranspeptidase.
RESULTS

The present study surveyed a total of 9,393 semiconductor workers comprising of 8,354 men (88.9%) and 1,039 women (11.1%). The participants’ age range was from 20 to 39 years (63.7%), and the frequency of drinking was to two to three times a month (50.9%). A total of 36.8% of the participants were smokers, and 63.3% were current non-smokers. The period of smoking was mostly 5–10 years (23.7%). A total of 78.3% had balanced eating (regular) habits. Fasting plasma glucose (FPG) levels at the last health check-up were related to sex (P < 0.01 by Student’s t-test), age (<0.01 by ANOVA), drinking frequency (<0.01), smoking status (<0.01), duration of smoking (<0.01), diet pattern (<0.01) and liver status (<0.01) in the univariate analysis. FPG levels were related to sweat exercise status (Table 1; P < 0.01 by ANOVA). In past diseases history, the FPG level with hypertension was the highest, and then stroke and heart disease (<0.01 by ANOVA; Table 1).

The geometric mean ± geometric standard deviation of FPG was 91.68 ± 1.09, 94.16 ± 1.09 and 95.54 ± 1.11 mg/dL in the first, second and last medical examinations, respectively. The health outcomes from general clinical examinations, such as cholesterol, triglyceride, blood pressure and so on, are described in Table 2. FPG was associated with AST (P = 0.03), ALT (<0.01) and GGT (<0.01) after adjustment for sex (men vs women), age (26–39, 40–49 and 50–59 years), BMI (weight [kg] / height [m]^2), dietary pattern (vegetarian, balanced diet and meat eater), drinking frequency (non-drinkers, two to three times/month, one to two times/week, three to four times/week and every day), smoking status (non-smokers, ex-smokers and smokers) and systolic blood pressure in multiple linear regression (n = 8,379; Table 3).

Table 4 shows the odds ratios for FPG by alteration of liver function enzymes, such as ALT, AST and GGT, from the first to last health check-up. All odds ratios for liver function enzymes were elevated from G1 (reference) to G4 after adjusting for age, BMI and sex (P for trend <0.01; Table 4). The levels of FPG at last health examination were increased from G1 to G4 (P < 0.01 for ALT, AST and GGT by ANOVA test; Figure 1).

DISCUSSION

The present study used the data of participants who had three cycles of health check-ups from 2002 to 2010 to study the impact of changes of enzymes levels on liver function. The highest abnormal liver function value in the first test was shown as the same highest abnormal liver function value in the second test in semiconductor workers. Therefore, the present study shows qualitatively that people with abnormal liver function levels can be diabetics, and the FPG level of recovered liver function is lower than the level of existing bad liver function or newly worse liver function. The FPG levels at the last check-up were the highest in the G4 group for each liver marker as shown in Figure 1. The meaning of this result is the absolute values of glucose in each group. The odds ratios for FPG >126 were the highest in G3 for AST and GGT, or in G4 for ALT, as shown in Table 4. The result represents the risk of prevalence of over 126 FPG, but we could explain the highest odds ratios in G3 for AST and GGT as being by chance.

In a previous study, the Bogalusa Heart’s Study showed that diabetes (n = 80) and prediabetes (n = 101) were significantly associated with ALT and GGT in healthy adults (average age 41.3 years)16. A previous prospective community-based study found an association between ALT and type 2 diabetes in an Asian population17. We also showed the independent predictive value of AST, ALT and GGT activity in diabetes after adjustment for risk factors including age, BMI, alcohol drinking frequency and blood pressure. The results of the present study
support previous longitudinal follow-up studies reporting an association between abnormal liver function and diabetes. However, epidemiological studies on FPG levels through alterations of liver function from continuous monitoring are limited. Scientists have shown that oxidative stress is related to liver function enzymes and diabetes. An animal model study showed that oxidative damage is associated with insulin resistance or insulin sensitivity and diabetic patients. Increased oxidative stress serves to facilitate transport of glutathione in the cell, increased glutathione is related to diabetes. GGT is used as an indicator of oxidative stress, and is also associated with diabetes in a previous study.

The benefits of the present study, first of all, are that the study was able to more precisely identify the FPG level related to changes of liver function from the check-up data collected from participants who underwent all three check-ups. Second, all of the existing studies have focused on the consequential occurrence of chronic disease according to the level of liver function, but in the present study, the risk of FPG level was confirmed through a regression model. Finally, our analysis of a large number of participants gave more statistically significant results and removed selection bias.

In conclusion, an association was observed between FPG levels and abnormal liver function in manufacturing workers. Abnormal liver function can be closely associated with the development of diabetes. In order to prevent further diabetes burden in people with abnormal liver enzyme levels, healthcare professionals should monitor them carefully.

**ACKNOWLEDGMENTS**

This study was financially supported by Samsung Electronics. There is no conflict of interest.

**REFERENCES**

1. King H, Rewers M, WHO Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. *Diabetes Care* 1993; 16: 157–177.
2. King H, Aubert RE, Herman WH. Global Burden of Diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care* 1998; 21: 1414–1431.
3. Park SW, Kim DJ, Min KW, et al. Current status of diabetes management in Korea using national health insurance database. *J Korean Diabetes Assoc* 2007; 31: 362–367.
4. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. *Diabetes 2001*; 50: 1844–1850.
5. Hanley AJG, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome. *Diabetes 2005*; 54: 3140–3147.
6. Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. *Diabetes Care* 2005; 28: 2913–2918.
7. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes 2002*; 51: 1889–1895.
8. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. *Diabetes Care* 2005; 28: 1757–1762.

9. Lee DH, Ha MH, Kim JH, et al. Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. *Diabetologia* 2003; 46: 359–364.

10. Lim J-S, Lee D-H, Park J-Y, et al. A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. *Clin Chem* 2007; 53: 1092–1098.

11. Kim DJ, Noh JH, Cho NH, et al. Serum γ-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. *Diabetol Med* 2005; 22: 1134–1140.

12. Lee DH, Silventoinen K, Jacobs DR, et al. γ-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. *J Clin Endocrinol Metab* 2004; 89: 5410–5414.

13. Lee D-H, Jacobs DR Jr, Gross M, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Clin Chem* 2003; 49: 1358–1366.

14. Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. *Clin Chem* 2007; 53: 686–692.

15. Mathiesen UL, Franzen LE, Åselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. *Dig Liver Dis* 2002; 34: 516–522.

16. Nguyen QM, Srinivasan SR, Xu JH, et al. Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the bogalusa heart study. *Diabetes Care* 2011; 34: 2603–2607.

17. Cho NH, Jang HC, Choi SH, et al. Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. *Diabetes Care* 2007; 30: 2566–2568.

18. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. *J Biochem Mol Toxicol* 2003; 17: 24–38.

19. West IC. Radicals and oxidative stress in diabetes. *Diabet Med* 2000; 17: 171–180.

20. Hirashima O, Kawano H, Motoyama T, et al. Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. *J Am Coll Cardiol* 2000; 35: 1860–1866.

21. de Souza Mda S, Srinzato YK, Lima PHO, et al. Oxidative stress status and lipid profiles of diabetic pregnant rats exposed to cigarette smoke. *Reprod Biomed Online* 2010; 20: 547–552.

22. Karp DR, Shimooku K, Lipsky PE. Expression of γ-Glutamyl Transpeptidase Protects Ramos B Cells from Oxidation-induced Cell Death. *J Biol Chem* 2001; 276: 3798–3804.